P-gp transporter and its role in neurodegenerative diseases

Current Topics in Medicinal Chemistry

Volumn 9, Issue 2, 2009, Pages 209-217

  Rapposelli, Simona ^a   Digiacomo, Maria ^a   Balsamo, Aldo ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

ALS; Alzheimer; Epilepsy; Hungtington; Neurodegenerative disorder; P glycoprotein; Parkinson

Indexed keywords

AMPA RECEPTOR; AMYLOID BETA PROTEIN; BETA SECRETASE INHIBITOR; BROMOCRIPTINE; BUPIDINE; CARBAMAZEPINE; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLOSPORIN A; ELACRIDAR; FELBAMATE; GLUTAMATE RECEPTOR ANTAGONIST; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; GSK 188909; LAMOTRIGINE; LEVODOPA; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENOBARBITAL; PHENYTOIN; PRION PROTEIN; RIFAMPICIN; RILUZONE; SIMVASTATIN; TARIQUIDAR; TOPIRAMATE; UNCLASSIFIED DRUG; VALSPODAR;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; EPILEPSY; HUMAN; HUNTINGTON CHOREA; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN SYNTHESIS INHIBITION; PROTEIN TRANSPORT; REVIEW; STRUCTURE ANALYSIS;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CREUTZFELDT-JAKOB SYNDROME; HUMANS; HUNTINGTON DISEASE; NEURODEGENERATIVE DISEASES; P-GLYCOPROTEIN; PARKINSON DISEASE;

EID: 63349089378     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609787521544     Document Type: Review

References (86)

1. Kim, W. S.; Weickert, C. S.; Garner, B. Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. J. Neurochem. 2008, 104, 1145-1166.
2. Löscher, W.; Potschka, H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 2005, 76, 22-76.
3. Cordon-Cardo, C.; O'Brien, J. P.; Casals, D.; Rittman-Grauer, L.; Biedler, J. L.; Melamed, M. R.; Bertino, J. R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at bloodbrain barrier sites. Proc. Natl. Acad. Sci. USA 1989, 86, 695-698.
4. Tatsuta, T.; Naito, M.; Oh-hara, T.; Sugawara, I.; Tsuruo, T. Functional involvement of P-glycoprotein in blood-brain barrier. J. Biol. Chem. 1992, 267, 20383-20391.
5. Tishler, D. M.; Weinberg, K. I.; Hinton, D. R.; Barbaro, N.; Annett, G. M.; Raffel, C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995, 36, 1-6.
6. Seetharaman, S.; Barrand, M. A.; Maskell, L.; Scheper, R. J. Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates. J. Neurochem. 1998, 70, 1151-1159.
7. Bartels, A. L.; Willemsen, A. T. M.; Kortekaas, R.; de Jong, B. M.; de Vries, R.; de Klerk, O.; van Oostrom, J. C. H.; Portman, A.; Leenders, K. L. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J. Neural. Transm. 2008, 115, 1001-1009.
8. Vogelgesang, S.; Cascorbi, I.; Kroemer, H. K.; Schroeder, E.; Pahnke, J.; Siegmund, W.; Keil, C.; Warzok, R. W.; Walker, L. C. Deposition of amyloid is inversely correlated with the expression of P-glycoprotein-implications on the possibility of prevention of Alzheimer's disease. Acta Neuropathol. 2001, 102, 545.
9. Fernandez, C.; Buyse, M.; German-Fattal, M.; Gimenez, F. Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. J. Pharm. Pharm. Sci. 2004, 7, 359-371.
10. Mcrae, M. P.; Brouwer, K. L. R.; Kashuba, A. D. M. Cytokine regulation of P-glycoprotein. Drug Metab. Rev. 2003, 35, 19-33.
11. Alafuzoff, I.; Iqbal, K.; Friden, H.; Adolfsson, R.; Winblad, B. Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol. 1987, 74, 209-225.
12. Arriagada, P.V.; Marzloff, K.; Hyman, B.T. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992, 42, 1681-1688.
13. Hussain, I.; Hawkins, J.; Harrison, D.; Hille, C.; Wayne,G.; Cutler, L.; Buck, T.; Walter, D.; Demont, E.; Howes, C.; Naylor, A.; Jeffrey, P.; Gonzalez, M. I.; Dingwall, C.; Redshaw, A. M. S.; Davis, J. B. Oral administration of a potent and selective nonpeptidic BACE-1 inhibitor decreases β-cleavage of amyloid precursor protein and amyloid-β production in vivo. J. Neurochem. 2007, 100, 802-809.
14. Meredith, Jr. J. E.; Thompson, L. A.; Toyn, J. H.; Marcin, L.; Barten, D. M.; Marcinkeviciene, J.; Kopcho, L.; Kim, Y.; Lin, A.; Guss, V.; Burton, C.; Iben, L.; Polson, C.; Cantone, J.; Ford, M.; Drexler, D.; Fiedler, T.; Lentz, K. A.; Grace, Jr. J. E.; Kolb, J.; Corsa, J.; Pierdomenico, M.; Jones, K.; Olson, R. E.; Macor, J. E.; Albright, C. F. P-glycoprotein efflux and other factors limit brain amyloid reduction by β-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice. J. Pharmacol. Exp. Ther. 2008, 326, 502-513.
15. Vogelgesang, S.; Cascorbi, I.; Schroeder, E.; Pahnke, J.; Kroemer, H. K.; Siegmund, W.; Kunert-Keil, C.; Walker, L. C.; Warzok, R. W. Deposition of Alzheimer's β-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly nondemented humans. Pharmacogenetics 2002, 12, 535-541.
16. Vogelgesang, S.; Kuhnke, D.; Jedlitschky, G.; Jucker, M.; Mosyagin, I.; Pahnke, J.; Cascorbi, I.; Kroemer, H. K.; Walker, L. C.; Warzok, R. W. P-glycoprotein (ABCB1) mediates transport of Alzheimer's beta-amyloid peptides. Acta Neuropathol. 2006, 112, 365-367.
17. Lam, F. C.; Liu, R.; Lu, P.; Shapiro, A. B.; Renoir, J. M.; Sharom, F. J.; Reiner, P. B. Beta-Amyloid efflux mediated by pglycoprotein. J. Neurochem. 2001, 76, 1121-1128.
18. Cirrito, J. R.; Deane, R.; Fagan, A. M.; Spinner, M. L.; Parsadanian, M.; Finn, M. B.; Jiang, H.; Prior, L.; Sagare, A.; Bales, K. R.; Paul, S.M.; Zlokovic, B. V.; Piwnica-Worms, D.; Holtzman, D. M. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest. 2005, 115, 3285-3290.
19. Fassbender, K.; Simons, M.; Bergmann, C.; Stroick, M.; Lutjohann, D.; Keller, P.; Runz, H.; Kuhl, S.; Bertsch, T.; von Bergmann, K.; Hennerici, M.; Beyreuther, K.; Hartmann, T. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2001, 98, 5856-5861.
20. Bogman, K.; Peyer, A.-K.; Torok, M.; Kusters, E.; Drewe, J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br. J. Pharmacol. 2001, 132, 1183-1192.
21. Talaga, P. β-amyloid aggregation inhibitors for the treatment of Alzheimer's disease: Dream or reality? Mini Rev. Med. Chem. 2001, 1, 175-186.
22. Castro, A.; Martinez, A. Peripheral and dual binding site acetylcholinesterase inhibitors: Implications in treatment of Alzheimer's disease. Mini Rev. Med. Chem. 2001, 1, 267-272.
23. Hernádez, F.; Lim, F.; Lucas, J. J.; Pérez-Martín, C.; Moreno, F.; Avila, J. Transgenic mouse models with Tau pathology to test therapeutic agents for Alzheimer's disease. Mini Rev. Med. Chem. 2002, 2, 51-58.
24. Asai, M.; Hattori, C.; Iwata, N.; Saido, T.C.; Sasagawa, N.; Szabo, B.; Hashimoto, Y.; Maruyama, K.; Tanuma, S.; Kiso, Y. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J. Neurochem. 2006, 96, 533-540.
25. Stachel, S. J.; Coburn, C. A.; Sankaranarayanan, S.; Price, E. A.; Wu, G.; Crouthamel, M.; Pietrak, B. L.; Huang, Q.; Lineberger, J.; Espeseth, A. S.; Jin, L.; Ellis, J.; Holloway, M. K.; Munshi, S.; Allison, T.; Hazuda, D.; Simon, A. J.; Graham, S. L.; Vacca, J. P. Macrocyclic inhibitors of beta-secretase: Functional activity in an animal model. J. Med. Chem. 2006, 49, 6147-6150.
26. Schapira, A. H. Etiology of Parkinson's disease. Neurobiology 2006, 66, S10-23.
27. Wood-Kaczmar, A.; Gandhi, S.; Wood, N. W. Understanding the molecular causes of Parkinson's disease. Trends Mol. Med. 2006, 12, 521-528.
28. Bain, L. J.; LeBlanc, G. A. Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein. Toxicol. Appl. Pharmacol. 1996, 141, 288-298.
29. Rajput, A.H. Environmental toxins accelerate Parkinson's disease onset. Neurology 2001, 56, 4-5.
30. Martel, F.; Calhau, C.; Soares-da-Silva, P.; Azevedo, I. Transport of H-3MPP+ in an immortalized rat brain microvessel endothelial cell line (RBE 4). NaunynSchmiedebergs Arch. Pharmacol. 2001, 363, 1-10.
31. Uversky, V. N.; Li, J.; Fink, A. L. Metal-triggered structural transformations, aggregation, and fiblillation of human α-synuclein. J. Biol. Chem. 2001, 276, 44284-44296.
32. Di Monte, D. A. The environment and Parkinson's disease: Is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol. 2003, 2, 531-538.
33. Drozdzik, M.; Bialecka, M.; Mysliwiec, K.; Honczarenko, K.; Stankiewicz, J.; Sych, Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: A possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 2003, 13, 259-263.
34. Kortekaas, R.; Leenders, K. L.; van Oostrom, J. C. H.; Vaalburg, W.; Bart, J.; Willemsen, A. T. M.; Hendrikse, N. H. Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo. Ann. Neurol. 2005, 57, 176-179.
35. Tan, E. K.; Khajavi, M.; Thornby, J. I.; Nagamitsu, S.; Jankovic, J.; Ashizawa, T. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 2000, 55, 533-538.
36. Lee, G.; Bendayan, R. Functional expression and localization of Pglycoprotein in the central nervous system: Relevance to the pathogenesis and treatment of neurological disorders. Pharm. Res. 2004, 21, 1313-1330.
37. Bartels, A. L.; Kortekaas, R.; Bart, J.; Willemsen, A. T. M.; de Klerk, O. L.; de Vries, J. J.; van Oostrom, J. C. H.; Leenders, K. L. Neurobiol. Aging. 2008, doi:10.1016/j.neurobiolaging. 2008.02.002.
38. Yokel, R. A. Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration, J. Alzheimers Dis. 2006, 10, 223-253.
39. Graff, C. L.; Pollack, G. M. Functional evidence for P-glycoprotein at the nose-brain barrier. Pharm. Res. 2005, 22, 86-93.
40. Kandimalla, K. K.; Donovan, M. D. Localization and differential activity of P-glycoprotein in the bovine olfactory and nasal respiratory mucosae. Pharm. Res. 2005, 22, 1121-1128.
41. Uhr, M.; Ebinger, M.; Rosenhagen, M. C.; Grauer, M. T. The antiparkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice. Neurosci. Lett. 2005, 383, 73-76.
42. Fisher, A.; Starr, M. S. Opposite effects of glutamate antagonists and antiparkinsonian drugs on the activities of DOPA decarboxylase and 5-HTP decarboxylase in the rat brain. Brain Res. 2000, 868, 268-274.
43. Klockgether, T.; Jacobsen, P.; Loschmann, P. A.; Turski, L. The antiparkinsonian agent budipine is an N-methyl-d-aspartate antagonist J. Neural. Transm. Park. Dis. Dement. 1993, 5, 101-106.
44. Soares-da-Silva, P.; Serrão, M. P.; Vieira-Coelho, M. A.; Pestana, M. Evidence for the involvement of P-glycoprotein on the extrusion of taken up L-DOPA in cyclosporine A treated LLC-PK1 cells. Br. J. Pharmacol. 1998, 123, 13-22.
45. Soares-Da-Silva, P.; Serrão, M. P. Outward transfer of dopamine precursor L-3,4-dihydroxyphenylalanine (L-dopa) by native and human P-glycoprotein in LLC-PK(1) and LLC-GA5 col300 renal cells. J. Pharmacol. Exp. Ther. 2000, 293, 697-704.
46. Vautier, S.; Lacomblez, L.; Chacun, H.; Picard, V.; Gimenez, F.; Farinotti, R.; Fernandez, C. Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse. Eur. J. Pharm. Sci. 2006, 27, 167-74.
47. van Dellen, A.; Grote, H. E.; Hannan, A. J. Gene-environment interactions, neuronal dysfunction and pathological plasticity in Huntington's disease. Clin. Exp. Pharmacol. Physiol. 2005, 32, 1007-1019.
48. Arrasate, M.; Mitra, S.; Schweitzer, E. S.; Segal, M. R.; Finkbeiner, S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 14, 805-810.
49. Patassini, S.; Giampà, C.; Martorana, A.; Bernardi, G.; Fusco, F. R. Effects of simvastatin on neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington's disease. Neurosci. Lett. 2008, 448, 166-169.
50. Cova, E.; Cereda, C.; Galli, A.; Curti, D.; Finotti, C.; Di Poto, C.; Corato, M.; Mazzini, G.; Ceroni, M. Modified expression of Bcl-2 and SOD1 proteins in lymphocytes from sporadic ALS patients. Neurosci. Lett. 2006, 399, 186-190.
51. Vogelgesang, S.; Glatzel, M.; Walker, L. C.; Kroemer, H. K.; Aguzzi, A.; Warzok, R. W. Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt-Jakob disease. Acta Neuropathol. 2006, 111, 436-443.
52. Armstrong, R. A.; Lantos, P. L.; Cairns, N. J. The spatial patterns of prion protein deposits in Creutzfeldt-Jakob disease: Comparison with beta-amyloid deposits in Alzheimer's disease. Neurosci. Lett. 2001, 298, 53-56.
53. Vogelgesang, S.; Warzok, R. W.; Cascorbi, I.; Kunert-Keil, C.; Schroeder, E.; Kroemer, H. K.; Siegmund, W.; Walker, L. C.; Pahnke, J. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 2004, 1, 121-125.
54. Mulder, D. W. Clinical limits of amyotrophic lateral sclerosis Adv. Neurol. 1982, 36, 15-22.
55. Deng, H. X.; Shi, Y.; Furukawa, Y.; Zhai, H.; Fu, R.; Liu, E.; Gorrie, G. H.; Khan, M. S.; Hung, W. Y.; Bigio, E. H.; Lukas, T.; Dal Canto, M. C.; O'Halloran, T. V.; Siddique, T. Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc. Natl. Acad. Sci. USA 2006, 103, 7142-7147.
56. Cleveland, D. W.; Rothstein, J. D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2001, 2, 806-819.
57. Okado-Matsumoto, A.; Fridovich, I. Amyotrophic lateral sclerosis: A proposed mechanism. Proc. Natl. Acad. Sci USA 2002, 99, 9010-9014.
58. Rothstein, J. D.; Tsai, G.; Kuncl, R. W.; Clawson, L.: Cornblath, D. R.; Drachman, D. B.; Pestronk, A.; Stauch, B. L.; Coyle, J. T. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann. Neurol. 1990, 28, 18-25.
59. Rothstein, J. D.; Martin, L. J.; Kuncl, R. W. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis.N. Engl. J. Med. 1992, 326, 1464-1468.
60. Bruijn, L. I.; Cudkowicz, M. Therapeutic targets for amyotrophic lateral sclerosis: Current treatments and prospects for more effective therapies. Expert. Rev. Neurother. 2006, 6, 417-428.
61. Bensimon, G.; Lacomblez, L.; Meininger, V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 1994, 330, 585-591.
62. Kriz, J.; Gowing, G.; Julien, J. P. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann. Neurol. 2003, 53, 429-436.
63. Chu, L. S.; Fang, S. H.; Zhou, Y.; Yu, G. L.; Wang, M. L.; Zhang, W. P.; Wei, E. Q. Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats, Acta Pharmacol. Sin. 2007, 28, 763-772.
64. Song, Y.; Wei, E. Q.; Zhang, W. P.; Zhang, L.; Liu, J. R.; Chen, Z. Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation, Neuroreport 2004, 15, 2181-2184.
65. Song, Y.; Wei, E. Q.; Zhang, W. P.; Ge, Q. F.; Liu, J. R.; Wang, M. L.; Huang, X. J.; Hu, X.; Chen, Z. Minocycline protects PC12 cells against NMDA-induced injury via inhibiting 5-lipoxygenase activation. Brain Res. 2006, 1085, 57-67.
66. Milane, A.; Fernandez, C.; Vautier, S.; Bensimon, G.; Meininger, V.; Farinotti, R. Minocycline and riluzole brain disposition: Interactions with p-glycoprotein at the blood-brain barrier. J. Neurochem. 2007, 103, 164-173.
67. Kirkinezos, I. G.; Hernandez, D.; Bradley, W. G.; Moraes, C. T. An ALS mouse model with a permeable blood-brain barrier benefits from systemic cyclosporine A treatment. J. Neurochem. 2004, 88, 821-826.
68. Sander, J. W. Some aspects of prognosis in the epilepsies: A review. Epilepsia 1993, 34, 1007-1016.
69. Regesta, G.; Tanganelli, P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res. 1999, 34, 109-122.
70. Yang, Z. H.; Liu, X. D. P-glycoprotein-mediated efflux of phenobarbital at the blood-brain barrier evidence from transport experiments in vitro. Epilepsy Res. 2008, 78, 40-49.
71. Lazarowski, A.; Riveros, D.; Sevlever, G.; Massaro, M.; Rabinowicz, A. L. 1-17-22 High expression of multidrug resistance gene (MDR-1) and persistant low levels of phenytoin (PHT) on a patient with refractory epilepsy due to tuberous sclerosis (TS). J. Neurol. Sci. 1997, 150 (suppl 1), S28.
72. Sisodiya, S. M.; Heffernan, J.; Squier, M. V. Over-expression of P-glycoprotein in malformations of cortical development. Neuroreport 1999, 10, 3437-3441.
73. Dombrowski, S. M.; Desai, S. Y.; Marroni, M.; Cucullo, L.; Goodrich, K.; Bingaman, W.; Mayberg, M. R.; Bengez, L.; Janigro, D. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001, 42, 1501-1506.
74. Sisodiya, S. M.; Lin, W. R.; Harding, B. N.; Squier, M. V.; Thom, M. Drug resistance in epilepsy: Expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002, 125, 22-31.
75. Luna-Tortós, C.; Fedrowitz, M.; Löscher, W. Several major antiepileptic drugs are substrates for human P-glycoprotein Neuropharmacology 2008, 55, 81364-1375.
76. Baltes, S.; Gastens, A. M.; Fedrowitz, M.; Potschka, H.; Kaever, V.; Löscher, W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacol. 2007, 52, 333-346.
77. Brandt, C.; Bethmann, K.; Gastens, A. M.; Löscher, W. The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy, Neurobiol. Dis. 2006, 24, 202-211.
78. Potschka, H.; Löscher, W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 2001, 42, 1231-1240.
79. Potschka, H.; Löscher, W. Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain. Neuroreport 2001, 12, 2387-2389.
80. Weiss, J.; Kerpen, C. J.; Lindenmaier, H.; Dormann, S. M.; Haefeli, W. E. Interaction of antiepileptic drugs with human Pglycoprotein in vitro, J. Pharmacol. Exp. Ther. 2003, 307, 262-267.
81. Benedetti, M.; Strolin, P.; Whomsley, R.; Espie, P.; Baltes, E. The role of the efflux transporter P-glycoprotein (P-GP) on the disposition of antiepileptic drugs: Implications for drug interactions. Focus on Epilepsy Research; Shawn, B.M.; Eds.; UCB Pharma, Nanterre (Fr), 2004, pp.199-220.
82. Hung, C. C.; Chen, C. C.; Lin, C. J.; Liou, H. H. Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs Pharmacogenet. Genom. 2008, 18, 390-402.
83. Bauer, B.; Hartz, A. M.; Pekcec, A.; Toellner, K.; Miller, D. S.; Potschka, H. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol. Pharmacol. 2008, 73, 1444-1453.
84. Kwan, P.; Brodie, M. J. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 2005, 46, 224-235.
85. Löscher, W. Mechanisms of drug resistance Epileptic Disord. 2005, 7 (Suppl. 1), S3-S9.
86. van Vliet, E. A.; van Schaik, R.; Edelbroek, P. M.; Redeker, S.; Aronica, E.; Wadman, W. J.; Marchi, N.; Vezzani, A.; Gorter, J. A. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 2006, 47, 672-680.